Published in J Infect Dis on November 01, 1977
Susceptibility of Gardnerella vaginalis to cephradine. Antimicrob Agents Chemother (1983) 0.84
In vitro studies with 5-fluorocytosine. Appl Microbiol (1969) 8.01
Variation in the susceptibility of strains of Staphylococcus aureus to oxacillin, cephalothin, and gentamicin. Antimicrob Agents Chemother (1976) 6.26
Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1991) 6.17
Vancomycin-resistant enterococci. Clin Microbiol Rev (2000) 5.61
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Incidence and characteristics of antibiotic-tolerant strains of Staphylococcus aureus. Antimicrob Agents Chemother (1978) 4.46
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Comparison of epidemiological markers used in the investigation of an outbreak of methicillin-resistant Staphylococcus aureus infections. J Clin Microbiol (1983) 2.95
In vitro activity of 5-fluorocytosine against Candida and Torulopsis species. Antimicrob Agents Chemother (1973) 2.54
Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400. J Infect Dis (1978) 2.51
In vitro antifungal activity of clotrimazole (Bay b 5097). Infect Immun (1971) 2.48
Sequential outbreaks of infection due to Klebsiella pneumoniae in a neonatal intensive care unit: implication of a conjugative R plasmid. J Infect Dis (1980) 2.33
Bioassay for hamycin and amphotericin B in serum and other biological fluids. Appl Microbiol (1969) 2.23
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
In vitro studies with combinations of 5-fluorocytosine and amphotericin B. Antimicrob Agents Chemother (1975) 2.10
Effect of storage and changes in bacterial growth phase and antibiotic concentrations on antimicrobial tolerance in Staphylococcus aureus. Antimicrob Agents Chemother (1980) 2.09
Ventriculostomy-related infections. A prospective epidemiologic study. N Engl J Med (1984) 1.96
Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis (1975) 1.88
New method for susceptibility testing with antifungal agents. Antimicrob Agents Chemother (1975) 1.83
In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole. Antimicrob Agents Chemother (1978) 1.82
Streptococcus faecium outbreak in a neonatal intensive care unit. J Clin Microbiol (1984) 1.81
In-vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia (1985) 1.76
Medical waste. Infect Control Hosp Epidemiol (1992) 1.75
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med (1987) 1.65
In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and 5-fluorocytosine. Antimicrob Agents Chemother (Bethesda) (1968) 1.62
In vitro studies with miconazole and miconazole nitrate. J Antimicrob Chemother (1977) 1.61
In vitro activities of five oral cephalosporins against aerobic pathogenic bacteria. Antimicrob Agents Chemother (1977) 1.60
In vitro studies with cefazolin. Antimicrob Agents Chemother (1974) 1.55
Validation of surgical wound classification in the operating room. Infect Control Hosp Epidemiol (1993) 1.53
In vitro and in vivo evaluation of antifungal agents. Eur J Clin Microbiol Infect Dis (1989) 1.52
Intracranial pressure: to monitor or not to monitor? A review of our experience with severe head injury. J Neurosurg (1982) 1.49
In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother (1984) 1.48
Antifungal activity of 5-fluorocytosine as measured by disk diffusion susceptibility testing. J Infect Dis (1977) 1.47
Characterization and control of intraamniotic infection in an urban teaching hospital. Am J Obstet Gynecol (1996) 1.46
Outbreak of vancomycin-resistant enterococci in a burn unit. Infect Control Hosp Epidemiol (2000) 1.45
Clinical infection control in gene therapy: a multidisciplinary conference. Infect Control Hosp Epidemiol (2000) 1.39
In vitro susceptibility testing with tobramycin. Antimicrob Agents Chemother (1972) 1.38
New medium for in vitro susceptibility studies with amphotericin B. Antimicrob Agents Chemother (1976) 1.37
Preparation and evaluation of 111In-labeled leukocytes as an abscess imaging agent in dogs. Radiology (1976) 1.36
Rapid determination of serum 5-fluorocytosine levels by high-performance liquid chromatography. Antimicrob Agents Chemother (1978) 1.36
Risk factors for intraamniotic infection: a prospective epidemiologic study. Am J Obstet Gynecol (1989) 1.35
Dematiaceous fungal pathogens isolated from nature. Mycopathologia (1980) 1.33
The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med (1981) 1.31
Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother (1993) 1.26
N-formimidoyl thienamycin (MK0787): in vitro study. Antimicrob Agents Chemother (1981) 1.26
Nosocomial sinusitis in patients in the medical intensive care unit: a prospective epidemiological study. Clin Infect Dis (1998) 1.24
Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis (1985) 1.22
5-fluorocytosine in human candidiasis. Antimicrob Agents Chemother (Bethesda) (1970) 1.22
Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling. Am J Respir Crit Care Med (1998) 1.21
Detection of candida antigenemia by counterimmunoelectrophoresis in patients with invasive candidiasis. J Infect Dis (1979) 1.20
Outbreak due to methicillin- and rifampin-resistant Staphylococcus aureus: epidemiology and eradication of the resistant strain from the hospital. Infect Control (1987) 1.20
In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens. Mycoses (1990) 1.20
Serotype B/C Cryptococcus neoformans isolated from patients in nonendemic areas. J Clin Microbiol (1982) 1.19
Urinary tract infections due to Candida albicans. Rev Infect Dis (1983) 1.19
Evaluation of fluorescence-based amplified fragment length polymorphism analysis for molecular typing in hospital epidemiology: comparison with pulsed-field gel electrophoresis for typing strains of vancomycin-resistant Enterococcus faecium. J Clin Microbiol (2000) 1.18
Therapeutic failures with miconazole. Antimicrob Agents Chemother (1978) 1.14
Laboratory evaluation of serological tests for systemic candidiasis: a cooperative study. J Clin Microbiol (1977) 1.10
Light sensitivity of prepared solutions of amphotericin B. Am Rev Respir Dis (1973) 1.09
In vivo studies with ambruticin in murine histoplasmosis. Antimicrob Agents Chemother (1978) 1.09
Exoantigen test for Cladosporium bantianum, Fonsecaea pedrosoi, and Phialophora verrucosa. J Clin Microbiol (1986) 1.08
Exoantigen test for differentiation of Exophiala jeanselmei and Wangiella dermatitidis isolates from other dematiaceous fungi. J Clin Microbiol (1984) 1.08
In vitro studies with ambruticin, a new antifungal antibiotic. Antimicrob Agents Chemother (1978) 1.07
Hepatic portal venous gas. A review and report on six new cases. Am J Med (1968) 1.06
In vitro susceptibility studies with netilmicin: comparison of a 10-microgram netilmicin disk with a standardized 10-microgram gentamicin disk. Antimicrob Agents Chemother (1978) 1.06
Near-drowning complicated by brain abscess due to Petriellidium boydii. Arch Neurol (1982) 1.05
A comparison of bifonazole (BAY H 4502) with clotrimazole in vitro. Sabouraudia (1982) 1.05
Sino-orbital aspergillosis treated with combination antifungal therapy. Successful therapy after failure with amphotericin B and surgery. JAMA (1980) 1.05
Risk factors for colonization or infection due to methicillin-resistant Staphylococcus aureus in HIV-positive patients: a retrospective case-control study. Infect Control Hosp Epidemiol (1999) 1.04
Evaluations of a patient isolator system. I. Evaluations of subsystems and procedures for sterilization and concurrent sanitation. Arch Environ Health (1965) 1.04
Enterobacter cloacae septicemia in a burn center: epidemiology and control of an outbreak. J Infect Dis (1979) 1.03
Josamycin and rosamicin: in vitro comparisons with erythromycin and clindamycin. Antimicrob Agents Chemother (1976) 1.01
Respiratory colonization with Pseudomonas putrefaciens after near-drowning in salt water. Am J Clin Pathol (1975) 1.00
Clinical and laboratory studies of a new micronized preparation of hamycin in systemic mycoses in man. Antimicrob Agents Chemother (Bethesda) (1967) 0.99
In-vitro inhibitory activities of 2 new orally absorbable imidazole derivatives: BAY n 7133 and BAY 1 9139. Sabouraudia (1983) 0.99
Brain abscess caused by Cladosporium trichoides. Arch Intern Med (1976) 0.97
In vivo studies with Bay b 5097. Antimicrob Agents Chemother (Bethesda) (1970) 0.97
Bioassay for miconazole. Antimicrob Agents Chemother (1977) 0.96
In vitro antibacterial activity of norfloxacin compared with eight other antimicrobial agents. Eur J Clin Microbiol (1983) 0.96
Diffusion disk susceptibility testing with cefaclor. Antimicrob Agents Chemother (1978) 0.95
Prospective study of microbial colonization of the nose and skin and infection of the vascular access site in hemodialysis patients. J Clin Microbiol (1988) 0.95
Isolation of cladosporium trichoides from nature. Mycopathologia (1977) 0.95
Outbreak of Salmonella typhimurium gastroenteritis due to an imported strain resistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole in a nursery. J Clin Microbiol (1984) 0.94
In vitro comparison of the antifungal activities of R34,000, miconazole and amphotericin B. Chemotherapy (1978) 0.93
Comparison of three methods to recover vancomycin-resistant enterococci (VRE) from perianal and environmental samples collected during a hospital outbreak of VRE. Infect Control Hosp Epidemiol (2000) 0.92
Interpretive criteria for cefamandole and cephalothin disk diffusion susceptibility tests. Antimicrob Agents Chemother (1979) 0.91
Biochemical serogrouping of clinical isolates of Cryptococcus neoformans. Diagn Microbiol Infect Dis (1987) 0.90
Studies on the mode of action of 5-fluorocytosine in Aspergillus species. Chemotherapy (1979) 0.89
Clinical predictors of infection of central venous catheters used for total parenteral nutrition. Infect Control Hosp Epidemiol (1990) 0.89
In vitro studies with cephanone. Antimicrob Agents Chemother (1974) 0.89
Evaluations of a patient isolator system. 3. Microbial contamination of the isolator interior. Arch Environ Health (1965) 0.89
In-vitro studies with four new antifungal agents: BAY n 7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002. Sabouraudia (1984) 0.88
Microbial growth patterns in intravenous fat emulsions. Am J Hosp Pharm (1983) 0.88
Diagnosis and management of infections of implantable devices used for prolonged venous access. Curr Clin Top Infect Dis (1992) 0.87
In vitro and in vivo activity of hamycin against Blastomyces dermatitidis. J Bacteriol (1969) 0.86
Cutaneous protothecosis. Successful treatment with amphotericin B. Arch Dermatol (1976) 0.86
Growth of Candida in casein hydrolysate solutions. N Engl J Med (1972) 0.86
Disk diffusion susceptibility tests with norfloxacin: confirmation of proposed interpretive criteria. Eur J Clin Microbiol (1983) 0.85